Anupam Sarma

Dr. Anupam Sarma

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ASAnupam Sarma
Anupam Sarma

22 January 2024 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
HBHimakshi Baruah
Himakshi Baruah
ASAnupam Sarma
Anupam Sarma
DBDebojeet Basak
Debojeet Basak
MDMridusmita Das
Mridusmita Das

24 July 2023 in Journal of Herbal Medicine
Verified
Journal Article
Closed access
ASAnupam Sarma
Anupam Sarma
RBRatnali Bania
Ratnali Bania
MDMalay K. Das
Malay K. Das

28 February 2021 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
ASAnupam Sarma
Anupam Sarma
RBRatnali Bania
Ratnali Bania
JDJuti Rani Devi
Juti Rani Devi
SDSatyendra Deka
Satyendra Deka

15 March 2019 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
ASAnupam Sarma
Anupam Sarma
MDMalay K. Das
Malay K. Das
The objective of the present investigation was to optimize and develop Tenofovir Disoproxil Fumarate (TDF) loaded Nanostrucrured Lipid Carriers (NLCs) with Compritol 888 ATO as solid lipid and oleic acid as liquid lipid by modified emulsion solvent diffusion method using Central Composite design (CCD). Three independent variables viz., Lipid to Drug ratio (A), Aqueous phase pH (B) and Sonication time (min) (C) were taken to investigate their effect on dependent variables viz., particle size (nm) (R1), PDI (R2) and % Entrapment Efficiency (%EE) (R3). Optimized formula of NLC was selected from the design space which was further optimized by changing the surfactants quantity. NLCs were evaluated for physicochemical, morphological, solid state characterization, and in-vitro dissolution in PBS pH 6.4, PBS 7.4 and ACSF. The average particle size was found to be 94.7 ± 15.70 nm with PDI of 0.380 ± 0.024 and 134.3 ± 9.71 nm with PDI of 0.358 ± 0.038 respectively for T4 and T5 NLC formulation. The zeta potential value of -17. ± 3.87 mV and -17.17 ± 1.05 mV and %EE of 35.5 ± 1.04 % and 34.2 ± 2.78 %. Overall, the above finding shows promising results in the area of developing non-invasive intranasal route as an alternative to oral route for brain delivery. Keywords: Central composite design, Intranasal, Neuro-AIDS, CNS targeting.

2 May 2016 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
MDMalay K Das
Malay K Das
ASAnupam Sarma
Anupam Sarma
TCTapash Chakraborty
Tapash Chakraborty